{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:03:52Z","timestamp":1773111832903,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GR1617\/14-1\/iPAD; SFB1160\/2_B5; RESIST\u2013EXC 2155\u2013Project ID 390874280; and CIBSS\u2013EXC-2189\u2013Project ID 390939984)"],"award-info":[{"award-number":["GR1617\/14-1\/iPAD; SFB1160\/2_B5; RESIST\u2013EXC 2155\u2013Project ID 390874280; and CIBSS\u2013EXC-2189\u2013Project ID 390939984)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1160 TP A04"],"award-info":[{"award-number":["SFB1160 TP A04"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["GAIN 01GM1910A"],"award-info":[{"award-number":["GAIN 01GM1910A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive multifocal leukoencephalopathy is a rare opportunistic infection of the brain by John Cunningham polyomavirus in immune-compromised patients. In cases where no overt option for immune reconstitution is available [e.g., in patients with primary immunodeficiency (PID)], the disease is lethal in the majority of patients. Immune checkpoint inhibition has been applied in recent years with mixed outcomes. We present four novel patients and the follow-up of a previously published patient suffering from progressive multifocal leukoencephalopathy (PML) due to PID and\/or hematologic malignancy who were treated with the immune checkpoint inhibitor pembrolizumab. In two patients with PID, symptoms improved and stabilized. One patient died because of worsening PML another of intracranial hemorrhage which was unrelated to PML or its treatment with pembrolizumab. The fifth patient suffered from PID and died of a pre-existing immune dysregulation, possibly exacerbated by pembrolizumab. The long-term follow-up of the first patient provides support for therapeutic decisions during this therapy and is the longest published clinical course of a patient with checkpoint inhibition for PML. We conclude that pembrolizumab can control PML symptoms long term in a subgroup of patients with PID, in our cases for 21 and 36\u00a0months. However, therapy must be started early because symptoms are only partially reversible. In light of severe adverse events, application of pembrolizumab is only justified if the prognosis for the individual patient is very poor.<\/jats:p>","DOI":"10.1007\/s00415-021-10682-8","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T13:03:03Z","timestamp":1625144583000},"page":"973-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and\/or hematologic malignancy: a case series of five patients"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-042X","authenticated-orcid":false,"given":"Timo","family":"Volk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Urbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Schluh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Rojas-Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodo","family":"Grimbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Rauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"1","key":"10682_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A (2021) Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17(1):37\u201351","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 7","key":"10682_CR2","doi-asserted-by":"publisher","first-page":"vii26","DOI":"10.1093\/neuonc\/nov174","volume":"17","author":"WT Curry","year":"2015","unstructured":"Curry WT, Lim M (2015) Immunomodulation: checkpoint blockade etc. Neuro Oncol 17(Suppl 7):vii26\u2013vii31","journal-title":"Neuro Oncol"},{"issue":"2","key":"10682_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","volume":"56","author":"K Grabmeier-Pfistershammer","year":"2011","unstructured":"Grabmeier-Pfistershammer K et al (2011) Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr 56(2):118\u2013124","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10682_CR4","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","volume":"109","author":"JY Zhang","year":"2007","unstructured":"Zhang JY et al (2007) PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109(11):4671\u20134678","journal-title":"Blood"},{"issue":"7077","key":"10682_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682\u2013687","journal-title":"Nature"},{"issue":"7235","key":"10682_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","volume":"458","author":"V Velu","year":"2009","unstructured":"Velu V et al (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235):206\u2013210","journal-title":"Nature"},{"issue":"11","key":"10682_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","volume":"32","author":"VA Evans","year":"2018","unstructured":"Evans VA et al (2018) Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 32(11):1491\u20131497","journal-title":"AIDS"},{"issue":"3","key":"10682_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","volume":"60","author":"CS Tan","year":"2012","unstructured":"Tan CS et al (2012) Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr 60(3):244\u2013248","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"10682_CR9","doi-asserted-by":"publisher","first-page":"ofz374","DOI":"10.1093\/ofid\/ofz374","volume":"6","author":"A Audemard-Verger","year":"2019","unstructured":"Audemard-Verger A et al (2019) Sustained response and rationale of programmed Cell Death-1-targeting for progressive multifocal leukoencephalopathy. Open Forum Infect Dis 6(10):ofz374","journal-title":"Open Forum Infect Dis"},{"issue":"17","key":"10682_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I et al (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380(17):1597\u20131605","journal-title":"N Engl J Med"},{"issue":"11","key":"10682_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/ene.14435","volume":"27","author":"Y Goereci","year":"2020","unstructured":"Goereci Y et al (2020) Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome. Eur J Neurol 27(11):2375\u20132377","journal-title":"Eur J Neurol"},{"issue":"11","key":"10682_CR12","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/ene.14433","volume":"27","author":"N Grassl","year":"2020","unstructured":"Grassl N et al (2020) Nivolumab for treatment of progressive multifocal leukoencephalopathy in Sezary syndrome. Eur J Neurol 27(11):2373\u20132374","journal-title":"Eur J Neurol"},{"issue":"2","key":"10682_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","volume":"25","author":"E Hoang","year":"2019","unstructured":"Hoang E et al (2019) Progressive multifocal leukoencephalopathy treated with nivolumab. J Neurovirol 25(2):284\u2013287","journal-title":"J Neurovirol"},{"issue":"6","key":"10682_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13365-020-00899-0","volume":"26","author":"A Holmes","year":"2020","unstructured":"Holmes A et al (2020) Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab. J Neurovirol 26(6):961\u2013963","journal-title":"J Neurovirol"},{"issue":"3","key":"10682_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1941874420902872","volume":"10","author":"RK Kapadia","year":"2020","unstructured":"Kapadia RK, Ney D (2020) Stabilization of progressive multifocal leukoencephalopathy after pembrolizumab treatment. Neurohospitalist 10(3):238\u2013239","journal-title":"Neurohospitalist"},{"issue":"6","key":"10682_CR16","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1212\/NXI.0000000000000628","volume":"6","author":"C Kupper","year":"2019","unstructured":"Kupper C et al (2019) Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 6(6):e628","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10682_CR17","doi-asserted-by":"crossref","unstructured":"Mahler C, et al. (2020) Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 7(4).","DOI":"10.1212\/NXI.0000000000000756"},{"issue":"11","key":"10682_CR18","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3201\/eid2511.190705","volume":"25","author":"C Medrano","year":"2019","unstructured":"Medrano C et al (2019) Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerg Infect Dis 25(11):2145\u20132147","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10682_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.eimc.2019.12.008","volume":"38","author":"M Mozo Ruiz","year":"2020","unstructured":"Mozo Ruiz M et al (2020) Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with Human Immunodeficiency Virus infection. Enferm Infecc Microbiol Clin 38(8):396\u2013397","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"10682_CR20","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1212\/NXI.0000000000000627","volume":"6","author":"M Pawlitzki","year":"2019","unstructured":"Pawlitzki M et al (2019) Ineffective treatment of PML with pembrolizumab: exhausted memory T-cell subsets as a clue? Neurol Neuroimmunol Neuroinflamm 6(6):e627","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"10682_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMc1817193","volume":"380","author":"S Rauer","year":"2019","unstructured":"Rauer S et al (2019) Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 380(17):1676\u20131677","journal-title":"N Engl J Med"},{"issue":"1","key":"10682_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10072-020-04582-4","volume":"42","author":"J Stogbauer","year":"2021","unstructured":"Stogbauer J et al (2021) Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report. Neurol Sci 42(1):357\u2013359","journal-title":"Neurol Sci"},{"issue":"6","key":"10682_CR23","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/bjh.16349","volume":"188","author":"M Uzunov","year":"2020","unstructured":"Uzunov M et al (2020) Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab. Br J Haematol 188(6):e82\u2013e84","journal-title":"Br J Haematol"},{"issue":"17","key":"10682_CR24","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMc1816198","volume":"380","author":"O Walter","year":"2019","unstructured":"Walter O et al (2019) Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med 380(17):1674\u20131676","journal-title":"N Engl J Med"},{"key":"10682_CR25","doi-asserted-by":"crossref","unstructured":"Roos-Weil D, et al. (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol.","DOI":"10.1007\/s00415-021-10414-y"},{"issue":"6","key":"10682_CR26","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1212\/NXI.0000000000000629","volume":"6","author":"RA Du Pasquier","year":"2019","unstructured":"Du Pasquier RA (2019) Pembrolizumab as a treatment for PML? Waiting for Godot. Neurol Neuroimmunol Neuroinflamm 6(6):e629","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10682_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/10428194.2018.1474523","volume":"60","author":"D Adrianzen Herrera","year":"2019","unstructured":"Adrianzen Herrera D et al (2019) Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series. Leuk Lymphoma 60(2):395\u2013401","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10682_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ana.410440309","volume":"44","author":"JR Berger","year":"1998","unstructured":"Berger JR et al (1998) Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44(3):341\u2013349","journal-title":"Ann Neurol"},{"issue":"5","key":"10682_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/ene.12963","volume":"23","author":"S Sainz-de-la-Maza","year":"2016","unstructured":"Sainz-de-la-Maza S et al (2016) Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol 23(5):919\u2013925","journal-title":"Eur J Neurol"},{"issue":"2","key":"10682_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/clin.1994.1023","volume":"70","author":"F Hulstaert","year":"1994","unstructured":"Hulstaert F et al (1994) Age-related changes in human blood lymphocyte. II. Subpopulations varying kinetics of percentage and absolute count measurements. Clin Immunol Immunopathol 70(2):152\u2013158","journal-title":"Clin Immunol Immunopathol"},{"issue":"5","key":"10682_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-3083.2011.02609.x","volume":"74","author":"EJ Schatorje","year":"2011","unstructured":"Schatorje EJ et al (2011) Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. Scand J Immunol 74(5):502\u2013510","journal-title":"Scand J Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10682-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10682-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10682-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T15:16:42Z","timestamp":1642778202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10682-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10682"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10682-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"13 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Declare no conflict of interest wrt the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients received pembrolizumab on a compassionate-use basis after informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients, guardians or next of kin have gave written informed consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}